Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.75 |
| ▸ | HRH1 | P35367 | 6/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.75 |
| ▸ | HTR2A | P28223 | 5/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.75 |
| ▸ | DRD3 | P35462 | 5/20 | 0.75 |
| ▸ | HTR2B | P41595 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.75 |
| ▸ | RAD52 | P43351 | 5/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.75 |
| ▸ | HTR1A | P08908 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL3194369 | 1.00 | LMNA (0.75) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069999 | 0.96 | LMNA (0.78) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394002 | 0.95 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL10394001 | 0.95 | LMNA (0.68) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069229 | 0.94 | LMNA (0.79) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1071642 | 0.91 | LMNA (0.84) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL246992 | 0.89 | MAPT (0.78) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL28456705 | 0.89 | MAPT (0.88) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| SCHEMBL21525461 | 0.89 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 | |
| Perphenazine SCHEMBL1069230 | 0.88 | MAPT (0.76) | LMNAMAPTMAPK1HRH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| EP-3643298-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | Sichuan University (CN) | 2020-04-29 | — | — | EP | claimed |
| US-20200069583-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | SICHUAN UNIVERSITY (CN) | 2020-03-05 | — | — | US | claimed |
| CN-107049932-A | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof | 四川大学 | 2017-08-18 | — | — | CN | claimed |
| CN-1484525-A | Combinations of drugs (E. G chlorpromazine and pentamidine) for the treatment of neoplastic disorders | — | 2004-03-24 | — | — | CN | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CHILDREN'S MEDICAL CENTER CORPORATION | 2025-04-22 | — | — | US | disclosed |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| CN-1484525-A | Combinations of drugs (E. G chlorpromazine and pentamidine) for the treatment of neoplastic disorders | — | 2004-03-24 | — | — | CN | disclosed |
| CN-1237901-A | Protein-stabilized pharmacologically active agents and methods for their preparation and use | VIVORX PHARMACEUTICALS INC (US) | 1999-12-08 | — | — | CN | disclosed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CALM1, RACK1, RRBP1 | DRD2 3409/4885LMNA 993/4885MAPT 2029/4885 |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | DRD2 3379/4885LMNA 919/4885MAPT 1757/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | DRD2 3053/4885LMNA 4062/4885MAPT 2847/4885 |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | DRD2 3379/4885LMNA 919/4885MAPT 1757/4885 |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CALM1, RACK1, CAMK2B | DRD2 3379/4885LMNA 919/4885MAPT 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.